已发表论文

乳腺癌中致癌蛋白CDC45的预后和免疫效应的功能分析和实验验证

 

Authors Zhang JN, Li LW, Cao MQ, Liu X, Yi ZL, Liu SS, Liu H 

Received 17 October 2024

Accepted for publication 20 December 2024

Published 9 January 2025 Volume 2025:17 Pages 11—25

DOI https://doi.org/10.2147/BCTT.S497975

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Pranela Rameshwar

Jia-Ning Zhang,1,2,* Lin-Wei Li,1,2,* Man-Qing Cao,1,2,* Xin Liu,1,2 Zi-Lu Yi,1,2 Sha-Sha Liu,1,2 Hong Liu1,2 

1The Second Surgical Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China; 2Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Hong Liu, Email liuhong_submit@tjmuch.com

Purpose: Cell division cycle protein 45 (CDC45) plays a crucial role in DNA replication. This study investigates its role in breast cancer (BC) and its impact on tumor progression.
Methods: We utilized the GEO database to screen differentially expressed genes (DEGs) and conducted enrichment analysis on these genes. We established a Nomogram model based on CDC45 and other clinical indicators. Additionally, we performed protein-protein interaction (PPI) network construction, drug sensitivity analysis, and immune correlation analysis of CDC45. The function of CDC45 was further verified through cell and animal experiments.
Results: CDC45 is highly expressed in most tumors, including BC. The expression level of CDC45 was significantly associated with age, sex, race, cancer stage, and molecular subtypes (all p < 0.05). CDC45 was incorporated into a Nomogram model, which showed moderate accuracy in predicting patient prognosis. We also analyzed the co-expression genes of CDC45, including TOPBP1, GINS2, MCM5, GINS1, GINS4, POLE2, MCM2, MCM6, MCM4, and MCM7. Furthermore, CDC45 expression was closely linked to immune infiltration levels, immune checkpoint inhibitors, and the therapeutic response to small molecule drugs. Finally, both in vitro and in vivo experiments confirmed the cancer-promoting effect of CDC45 in BC.
Conclusion: The expression level of CDC45 is linked to the prognosis, immune infiltration, and drug sensitivity of BC. In vitro and in vivo experiments have confirmed that CDC45 acts as a cancer-promoting protein in breast cancer.

Keywords: breast cancer, CDC45, prognosis, immunity, animal experiment